Investors

Kalabre monitors patients for the first signs of developing infections, often detected days before clinical signs of illness. Used once in the morning, Kalabre will predict the likelihood of a bacterial or viral infection accurately more often than 96% of the time.

Kalabre in base

Kalabre early detection monitor

Graph of a Pad

Kalabre proprietary graph

The Kalabre algorithm correlates a basal metabolic indicator, obtained by patients immediately upon waking, and a key lung function, obtained upon rising, and then displays the results on both the Kalabre and as a Kalabre graph on their physicians’ mobile devices and desktops.

Initial target markets include individuals with lung function issues, such as patients with COPD, which includes emphysema and chronic bronchitis, and moderate to severe asthma. These patient populations exceed forty-five million in the United States alone.

In addition to Kalabre device sales, subscriptions to the Kalabre Portal, which connects patients with their healthcare providers, will also be a major source of revenue.

Kalabre will keep patients out of the hospital, being treated at their physicians’ clinics.

Kalabre allows physicians to monitor their patients more effectively for developing infections, and then recommend the best courses of treatment. And doctors can be paid to review their patients’ data through new telehealth insurance reimbursement codes.

Who Needs Kalabre the most?

  • COPD, Cystic Fibrosis, and Asthma Patients - 40 million patients often needing hospitalization due to the late intervention of exacerbations caused by respiratory infections
  • CHF Patients – 5.5 million needing to detect infections early

Potential future applications or indications:

  • Pregnancy Patients - 6.4 million being treated; infections affect mother and baby
  • Oncology Patients – 1.7 million new cases each year; infections a major concern
  • Senior Population - 47 million needing to detect infections early
  • Post-Surgery Patients - .5 million return to hospitals with infections
  • Department of Homeland Security – 1.6 million healthcare workers at risk in hospitals
  • And anyone who wants to detect their likelihood of infection before they experience symptoms

Kalabre is being developed by Biosymtec Medical, Inc., a medical product research, design and marketing company based in the United States. The conceptual engineering phase has already been completed for the Kalabre monitor and the application portal. The final design phase will result in a prototype.

To learn more about Kalabre, please visit the Kalabre website. For investment opportunity information contact Clark M. Barousse.

Clark Barousse

Clark M. Barousse
President & CEO Biosymtec Medical, Inc.
cbarousse@biosymtecmedical.com
901-877-4070